SmartPrEP App for HIV Prevention
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a mobile app designed to help cisgender and transgender women adhere to their PrEP (pre-exposure prophylaxis) routine, which prevents HIV infection. The app, called Making PrEP Smart, also supports HIV self-testing and partner testing, making it a comprehensive tool for HIV prevention. Participants should be HIV-negative women, either already on PrEP or ready to start, and must have a smartphone with active service. The study aims to evaluate the app's effectiveness for daily PrEP use and gather user feedback on its features. As an unphased trial, it offers participants the chance to contribute to innovative HIV prevention strategies and improve health outcomes for women.
Do I need to stop my current medications to join the trial?
You may need to stop taking certain medications if they could interact negatively with Truvada or Descovy, which are part of the trial. This includes some hepatitis C treatments, certain HIV medications, and drugs that affect kidney function. It's best to discuss your current medications with the study team to see if any changes are needed.
What prior data suggests that the SmartPrEP app is safe for use in supporting PrEP adherence?
Research has shown that the SmartPrEP app is designed to help users remember to take their PrEP medication. PrEP, or pre-exposure prophylaxis, is a medicine that helps prevent HIV. The app also assists with HIV testing for both the user and their partner.
There is no direct data yet on the safety of using the SmartPrEP app, but it is important to note that the app does not involve any drugs or medical procedures. It simply sends reminders and offers support for testing, making physical side effects unlikely.
For those already taking PrEP, the app aims to simplify remembering doses and getting tested for HIV. This could enhance the effectiveness of PrEP. The main goal is to make staying healthy simpler and more organized.12345Why are researchers excited about this trial?
Researchers are excited about the SmartPrEP App for HIV prevention because it introduces a digital approach to enhancing PrEP (pre-exposure prophylaxis) adherence, which is crucial for preventing HIV infection. Unlike traditional methods that rely solely on individual discipline to take medication consistently, this app provides tailored reminders and supports HIV self-testing and partner testing, specifically designed for cis- and transgender women. This innovative use of mobile technology aims to increase accessibility and engagement, potentially leading to higher adherence rates and better health outcomes.
What evidence suggests that the SmartPrEP app is effective for PrEP adherence in HIV prevention?
Research shows that mobile apps can help people adhere to taking PrEP, a medication that prevents HIV. Studies have found that digital tools send personalized reminders and support, making it easier for users to take PrEP regularly. For example, the UPrEPU app successfully helped men who have sex with men maintain their PrEP routine. This trial will evaluate the SmartPrEP app, which aims to help cisgender and transgender women take PrEP consistently. By encouraging regular use of PrEP and promoting HIV testing, the app aims to reduce the risk of HIV infection.12567
Who Is on the Research Team?
Jessica Justman, MD
Principal Investigator
Columbia University
Are You a Good Fit for This Trial?
This trial is for HIV-negative cisgender and transgender women over 18, who are sexually active or use injection drugs, and are either starting PrEP or have been on it for less than three months. They must have a mobile phone with at least a 3G network, normal kidney function, no acute HIV symptoms, not be pregnant or breastfeeding, and plan to stay in the NYC area for the next year.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants use the SmartPrEP app and receive PrEP medication with adherence counseling and HIV testing over a 12-month period
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Making PrEP Smart
Find a Clinic Near You
Who Is Running the Clinical Trial?
Columbia University
Lead Sponsor
Gilead Sciences
Industry Sponsor
Daniel O'Day
Gilead Sciences
Chief Executive Officer since 2019
MBA from Columbia University
Dietmar Berger
Gilead Sciences
Chief Medical Officer
MD and PhD from Albert-Ludwigs University School of Medicine